Sanguine Overview
- Year Founded
-
2010

- Status
-
Private
- Employees
-
119

- Latest Deal Type
-
Later Stage VC
- Investors
-
22
Sanguine General Information
Description
Developer of a translational biomedical and biospecimen collection platform designed for research purposes. The company's platform offers direct-to-patient engagement, in-home collection of annotated biospecimens, and apheresis product offerings, enabling researchers to access and conduct prospective study designs and obtain clinically relevant biomarker data.
Contact Information
Website
www.sanguinebio.comCorporate Office
- 400 West Cummings Park
- Suite 3050
- Woburn, MA 01801
- United States
Corporate Office
- 400 West Cummings Park
- Suite 3050
- Woburn, MA 01801
- United States
Sanguine Timeline
Sanguine Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
11. Later Stage VC | 15-Aug-2024 | Completed | Generating Revenue | |||
10. Debt - General | 31-Oct-2023 | Completed | Generating Revenue | |||
9. Later Stage VC | 09-Jan-2023 | Completed | Generating Revenue | |||
8. Secondary Transaction - Private | 16-Mar-2022 | Completed | Generating Revenue | |||
7. Debt - PPP | 08-Apr-2020 | Completed | Generating Revenue | |||
6. Grant | 01-Feb-2019 | Completed | Generating Revenue | |||
5. Accelerator/Incubator | 18-Mar-2018 | Completed | Generating Revenue | |||
4. Later Stage VC | 01-Jul-2016 | Completed | Generating Revenue | |||
3. Later Stage VC (Series A) | 29-May-2015 | $5.53M | $7.03M | Completed | Startup | |
2. Seed Round | 21-Feb-2013 | $1.5M | $1.5M | Completed | Startup |
Sanguine Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Sanguine Comparisons
Industry
Financing
Details
Sanguine Competitors (2)
One of Sanguine’s 2 competitors is Asuragen, a Formerly VC-backed company based in Austin, TX.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Asuragen | Formerly VC-backed | Austin, TX | ||||
Myriad Genetics | Corporation | Salt Lake City, UT |
Sanguine Signals
Sanguine Investors (22)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Albany Capital (Australia) | Venture Capital | Minority | ||
BroadOak Capital Partners | Growth/Expansion | Minority | ||
Catalio Capital Management | Venture Capital | Minority | ||
Vitamin Capital | Venture Capital | Minority | ||
Neman Ventures | Venture Capital | Minority |
Sanguine FAQs
-
When was Sanguine founded?
Sanguine was founded in 2010.
-
Where is Sanguine headquartered?
Sanguine is headquartered in Woburn, MA.
-
What is the size of Sanguine?
Sanguine has 119 total employees.
-
What industry is Sanguine in?
Sanguine’s primary industry is Other Healthcare Technology Systems.
-
Is Sanguine a private or public company?
Sanguine is a Private company.
-
What is Sanguine’s current revenue?
The current revenue for Sanguine is
. -
How much funding has Sanguine raised over time?
Sanguine has raised $27.5M.
-
Who are Sanguine’s investors?
Albany Capital (Australia), BroadOak Capital Partners, Catalio Capital Management, Vitamin Capital, and Neman Ventures are 5 of 22 investors who have invested in Sanguine.
-
Who are Sanguine’s competitors?
Asuragen and Myriad Genetics are competitors of Sanguine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »